✦ LIBER ✦

… But new treatments challenge phase I thinking

✍ Scribed by David McNamee

Book ID: 119503964
Publisher: The Lancet
Year: 1997
Tongue: English
Weight: 33 KB
Volume: 349
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(05)62964-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Electrochemotherapy, a new antitumor tre

Electrochemotherapy, a new antitumor treatment. First clinical phase I-II trial

✍ Michel Belehradek; Christian Domenge; Bernard Luboinski; Stéphane Orlowski; Jean 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 680 KB

Significant others of I.V. drug abusers

Significant others of I.V. drug abusers with AIDS: New challenges for drug treatment programs

✍ Greif, Geoffrey L.; Porembski, Edmund 📂 Article 📅 1987 🏛 Elsevier Science 🌐 English ⚖ 457 KB

I025 THE GLOBAL CHALLENGE OF PPH AND NEW

I025 THE GLOBAL CHALLENGE OF PPH AND NEW FIGO GUIDELINES ON THE PREVENTION AND TREATMENT OF PPH WITH MISOPROSTOL

✍ Arulkumaran, S. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 54 KB

Phase I clinical trials with WAL 2014, a

Phase I clinical trials with WAL 2014, a new muscarinic agonist for the treatment of Alzheimer's disease

✍ Waclaw S. Adamus; Joachim P. Leonard; Wolfgang Tröger 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 668 KB

P98 Extreme body growth and protein accr

P98 Extreme body growth and protein accretion under normal serum IGF-I concentrations in male but not in female mice – new models and new challenges for the somatomedin hypothesis

✍ M. Sawitzky; U. Renne; M. Langhammer; J. Brenmoehl; A. Zeissler; M. Bielohuby; M 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 86 KB

Palladium-103: A new radioactive source

Palladium-103: A new radioactive source in the treatment of unresectable carcinoma of the pancreas: A phase I–II study

✍ Nori, Dattatreyudu; Merimsky, Ofer; Osian, Adrian D.; Heffernan, Margot; Cortes, 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 482 KB 👁 2 views

not show any improvement in the median survival rate over 1-125 due to the advanced stage cancer in the majority of patients in the study.